Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/17/2025 | $16.00 → $20.00 | Buy | H.C. Wainwright |
| 4/29/2025 | $47.00 | Overweight | Cantor Fitzgerald |
| 1/31/2025 | $26.00 | Mkt Outperform | JMP Securities |
| 7/29/2024 | $35.00 | Buy | TD Cowen |
| 3/28/2023 | $18.00 | Outperform | Evercore ISI |
| 9/29/2021 | $20.00 | Buy | Jefferies |
H.C. Wainwright reiterated coverage of Astria Therapeutics with a rating of Buy and set a new price target of $20.00 from $16.00 previously
Cantor Fitzgerald initiated coverage of Astria Therapeutics with a rating of Overweight and set a new price target of $47.00
JMP Securities initiated coverage of Astria Therapeutics with a rating of Mkt Outperform and set a new price target of $26.00
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
S-8 - Astria Therapeutics, Inc. (0001454789) (Filer)
10-Q - Astria Therapeutics, Inc. (0001454789) (Filer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
-- Results Support Potential for STAR-0310 to be Best-in-Class OX40 Antagonist -- -- STAR-0310 Exhibits Longest-in-Class Half-Life of 68 Days and Cytokine Suppression Lasting At Least 20 Weeks After a Single 300 mg SC Injection, Supporting Potential Every-Six-Month Administration -- -- STAR-0310 Was Well-Tolerated, with no ADCC-Related Treatment-Emergent Adverse Events, Supporting a Wider Therapeutic Window with the Potential to Drive Greater Efficacy than First-Generation OX40 Antibodies -- -- Results to be Presented by Dr. Stephan Weidinger, M.D., Ph.D. on September 18, at 4:00pm CEST -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing lif
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 128,000 shares of Astria's common stock on September 2, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted as an inducement material to three employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $6.59, which is equal to the closing price of
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial data from the Phase 1a trial of STAR-0310 at the European Academy of Dermatology & Venereology (EADV) Congress 2025, taking place September 17-20, 2025 in Paris, France. Stephan Weidinger, M.D., Ph.D., Director and Chair of the Department of Dermatology and Allergy at the University Medical Center Kiel, Schleswig-Holstein, will present initial results from the Phase 1a trial of STAR-0310 in healthy participants in a late-breaking oral presentation titled, "Demonstration of Early Proof-of-Conce
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
SC 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. "It is a pleasure to welcome Sunil to our Board of Directors," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "His extensive drug development and clinical expertise strongly complements our Board's skills and experiences, and we look forward to his contributions as we continue to advance our programs into later-stage cl
-- STAR-0215 Dosed Once or Twice Over 6 Months Reduced Monthly Attack Rates by 90-96%, Supporting Chronic Dosing 2 or 4 Times Per Year -- -- 92-100% Decrease in Moderate or Severe Attacks and 91-95% Reduction in Attacks Requiring Rescue Medications with STAR-0215 -- -- Very Well-Tolerated with No Serious Adverse Events and No Discontinuations -- -- Phase 3 Initiation on Track for Q1 2025, with Top-Line Results Expected by Year End 2026 -- -- Current Cash Expected to Fund Company into Mid-2027 -- -- Conference Call Today at 8:30am ET – Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, will report third quarter 2023 financial results before the Nasdaq Global Market open on Monday, November 13, 2023. Jill C. Milne, Ph.D., Chief Executive Officer, will host a conference call and webcast at 8:30am ET to provide an update on corporate developments and to discuss third quarter financial results. Webcast Information: Interested parties may join the webcast via the Investors section of the Astria website, www.astriatx.com, or with the following link: https://lifescievents.com/event/astria-2/. Please connect to the webca
-- Differentiated Preclinical Lead Candidate STAR-0310 to be Developed as a Potential Best-in-Class Long-Acting Treatment for Atopic Dermatitis – -- Conference Call and Webcast to be Held on October 12, 2023 at 8:30am ET -- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it has entered into a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential treatment of atopic dermatitis (AD) and potentially for other allergic and immunological diseases. Astria plans to develop the lead candidate, called STAR-03